Benefits
Immune system modulation and enhancement
Astragalus polysaccharides activate macrophages, NK cells, T-cells, and B-cells through multiple pattern recognition receptor pathways. Human studies, mostly small and of variable quality, suggest reduced upper respiratory infection frequency; effects on vaccine response and NK cell activity rest largely on laboratory and animal data.
Telomerase-activating activity (cycloastragenol)
Cycloastragenol and astragaloside IV activate telomerase reverse transcriptase (hTERT) — the enzyme that extends telomeres. A 12-month TA-65® study showed significant reduction in the percentage of critically short telomeres and improvements in immune aging biomarkers, This human telomere data comes from a purified TA-65 product rather than whole astragalus, and its open-label design without a placebo group limits how much can be concluded.
Cardiovascular and kidney protection
Astragalus polysaccharides demonstrate protective effects in cardiac and renal tissue — supporting heart and kidney tissue in preclinical models and some lower-quality human studies. A Cochrane review of astragalus in chronic kidney disease found possible benefit but rated the overall evidence as low quality. Multiple Chinese clinical trials (though often lower quality) support cardiovascular adjunct applications.
Blood sugar regulation
In laboratory and animal studies, APS has been reported to improve insulin sensitivity, lower fasting blood glucose, and protect pancreatic beta cells from oxidative damage. Most of this evidence comes from animal models; human trials are limited, small, and generally lower quality, so blood-sugar benefits in people are not well established.
Adaptogenic and anti-aging properties
Astragalus has traditionally been used as a tonic and anti-aging herb in TCM. Direct human evidence for cortisol reduction or increased energy is limited and preliminary. The combination of immune modulation, telomerase activation, antioxidant activity, and metabolic benefits makes astragalus a popular longevity-oriented botanical, though most of these effects rest on traditional use and preclinical data rather than strong human outcomes.
Mechanism of action
TLR-4 and Dectin-1 immune receptor activation
Astragalus polysaccharides bind TLR-4 and Dectin-1 pattern recognition receptors on macrophages and dendritic cells, activating NF-κB-dependent innate immune responses including cytokine production, NK cell activation, and dendritic cell maturation. This innate immune priming enhances both infection defense and vaccine response efficacy.
Telomerase reverse transcriptase (hTERT) activation
Cycloastragenol activates hTERT transcription by binding and activating protein kinase C (PKC) signaling cascades that upregulate the TERT gene promoter. Astragaloside IV may act through similar mechanisms. Telomerase activation extends critically short telomeres in immune cells, potentially reversing one aspect of cellular immunosenescence.
PI3K/Akt/mTOR pathway modulation for cellular protection
Astragalosides modulate the PI3K/Akt survival pathway in cardiac, renal, and immune cells — reducing apoptosis in stressed cells, improving mitochondrial membrane potential, and supporting cellular energy metabolism under hypoxic or inflammatory conditions.
Clinical trials
Single-arm, open-label observational study of TA-65® (cycloastragenol-derived telomerase activator from Astragalus, 5–10 mg/day) in 114 healthy adults aged 53-87 over 12 months. Outcomes: telomere length distribution, T-cell immunosenescence markers (CD8+CD28- senescent cells), cytomegalovirus seropositivity. (Harley, Liu et al. 2011, Rejuvenation Res)
114 healthy adults aged 53-87. 12-month observational.
TA-65® reduced the percentage of critically short telomeres in peripheral blood lymphocytes vs baseline. Reduced CD8+CD28- senescent T-cell populations, particularly in CMV-seropositive subjects. Authors propose telomerase activation mechanism. Important limitations: open-label without placebo; 'critically short' telomere measure is specialized; the broader mean telomere length effect is more debated. Independent replications limited.
Evidence review of randomized controlled trials examining astragalus (Astragalus membranaceus) preparations for prevention and treatment of upper respiratory infections in adults and children. (narrative summary; individual trials are not cited here)
Pooled across multiple clinical trials.
Astragalus supplementation associated with reduced frequency of upper respiratory infections and shortened duration of illness in most included studies. Heterogeneous formulations (root powder, decoction, standardized extract) and variable methodology limit pooled estimates. Immune-modulating effects (e.g., enhanced NK cell activity, T-cell proliferation) provide mechanistic plausibility. Best evidence supports astragalus as a complementary immunomodulator rather than acute treatment.